Second Sight Medical Products Inc. [NASDAQ: EYES] plunged by -$0.31 during the normal trading session on Monday and reaching a high of $15.82 during the day while it closed the day at $14.89. The company report on March 5, 2021 that Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System.
Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced U.S. Food and Drug Administration (FDA) has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development.
In addition to ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing.
Second Sight Medical Products Inc. stock has also gained 26.51% of its value over the past 7 days. However, EYES stock has inclined by 919.86% in the 3 months of the year. Over the past six months meanwhile, it has gained 1898.66% and gained 696.26% year-on date.
The market cap for EYES stock reached $254.77 million, with 23.12 million shares outstanding and 13.25 million shares in the current float. Compared to the average trading volume of 22.84M shares, EYES reached a trading volume of 16961496 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Second Sight Medical Products Inc. [EYES]:
Dougherty & Company have made an estimate for Second Sight Medical Products Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 13, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 06, 2015, representing the official price target for Second Sight Medical Products Inc. stock.
The Average True Range (ATR) for Second Sight Medical Products Inc. is set at 2.45, with the Price to Sales ratio for EYES stock in the period of the last 12 months amounting to 509.54. The Price to Book ratio for the last quarter was 744.50, with the Price to Cash per share for the same quarter was set at 0.14.
EYES stock trade performance evaluation
Second Sight Medical Products Inc. [EYES] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.51. With this latest performance, EYES shares gained by 502.83% in over the last four-week period, additionally plugging by 1898.66% over the last 6 months – not to mention a rise of 386.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EYES stock in for the last two-week period is set at 75.42, with the RSI for the last a single of trading hit 75.41, and the three-weeks RSI is set at 75.07 for Second Sight Medical Products Inc. [EYES]. The present Moving Average for the last 50 days of trading for this stock 3.49, while it was recorded at 13.68 for the last single week of trading, and 1.65 for the last 200 days.
Second Sight Medical Products Inc. [EYES]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Second Sight Medical Products Inc. [EYES] shares currently have an operating margin of -905.50 and a Gross Margin at +36.31. Second Sight Medical Products Inc.’s Net Margin is presently recorded at -994.14.
Return on Total Capital for EYES is now -472.14, given the latest momentum, and Return on Invested Capital for the company is -528.01. Return on Equity for this stock declined to -648.56, with Return on Assets sitting at -246.27. When it comes to the capital structure of this company, Second Sight Medical Products Inc. [EYES] has a Total Debt to Total Equity ratio set at 35.77. Additionally, EYES Total Debt to Total Capital is recorded at 26.34, with Total Debt to Total Assets ending up at 15.68. Long-Term Debt to Equity for the company is recorded at 32.51, with the Long-Term Debt to Total Capital now at 23.94.
Reflecting on the efficiency of the workforce at the company, Second Sight Medical Products Inc. [EYES] managed to generate an average of -$299,929 per employee. Receivables Turnover for the company is 7.05 with a Total Asset Turnover recorded at a value of 0.25.Second Sight Medical Products Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.
Earnings per share (EPS) analysis for Second Sight Medical Products Inc. [EYES] stock
With the latest financial reports released by the company, Second Sight Medical Products Inc. posted -0.48/share EPS, while the average EPS was predicted by analysts to be reported at -0.48/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EYES.
Second Sight Medical Products Inc. [EYES]: Insider Ownership positions
There are presently around $10 million, or 3.00% of EYES stock, in the hands of institutional investors. The top three institutional holders of EYES stocks are: VANGUARD GROUP INC with ownership of 405,702, which is approximately 210.483% of the company’s market cap and around 43.09% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 72,244 shares of the stock with an approximate value of $1.08 million in EYES stocks shares; and TOWER RESEARCH CAPITAL LLC (TRC), currently with $0.58 million in EYES stock with ownership of nearly New of the company’s market capitalization.
Positions in Second Sight Medical Products Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 14 institutional holders increased their position in Second Sight Medical Products Inc. [NASDAQ:EYES] by around 434,804 shares. Additionally, 8 investors decreased positions by around 690,108 shares, while 4 investors held positions by with 439,940 shares. The mentioned changes placed institutional holdings at 684,972 shares, according to the latest SEC report filing. EYES stock had 7 new institutional investments in for a total of 114,403 shares, while 6 institutional investors sold positions of 595,791 shares during the same period.